Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug4026 | Tocilizumab (TCZ) Wiki | 0.71 |
| drug3738 | Standard of care Wiki | 0.20 |
| drug2916 | Placebo Wiki | 0.04 |
| Name (Synonyms) | Correlation |
|---|
Navigate: Correlations HPO
There is one clinical trial.
The disease caused by the SARS-CoV-2 virus is a viral disease that infects the lungs, producing flu-like symptoms. Elderly infected patients and/or those with co-morbidities may suffer from acute respiratory distress syndrome due to pneumonia (COVID-19 disease). Given the high transmission, this virus has spread in recent months from Wuhan (China) to the whole world, becoming a global emergency pandemic. The lack of curative treatment for this disease justifies the need to carry out clinical trials that provide quality evidence on treatment options. Given the pathophysiology of the disease, which involves an uncontrolled inflammatory response of alveolar cells, a treatment that attenuates the cytokine cascade could be key in rescuing the patient's lung tissue. Mesenchymal cells, due to their immunoregulatory potential and regenerative capacity, can be an effective treatment for patients infected with the SARS-CoV-2 virus. In the present study we propose a therapy with undifferentiated allogeneic mesenchymal cells derived from umbilical cord tissue, a treatment whose safety has already been described in other clinical trials and that shows promising results in pilot studies carried out in China.
Description: Percentage of patients death due to lung involvement due to SARS-CoV-2 virus infection at 28 days of treatment
Measure: Mortality due to lung involvement due to SARS-CoV-2 virus infection at 28 days of treatment Time: 28 daysDescription: Percentage of patients death due to lung involvement due to SARS-CoV-2 virus infection at 14 days of treatment
Measure: Mortality due to lung involvement due to SARS-CoV-2 virus infection at 14 days of treatment Time: 14 daysDescription: Percentage of patients death due to any cause at 28 days of treatment
Measure: Mortality from any cause at 28 days Time: 28 daysDescription: Number of days without mechanical respirator and without vasopressor treatment for 28 days
Measure: Days without mechanical respirator and without vasopressor treatment for 28 days Time: 28 daysDescription: Percentage of patients alive without mechanical ventilation and without vasopressors on day 28
Measure: Patients alive without mechanical ventilation and without vasopressors on day 28 Time: 28 daysDescription: Percentage of patients alive and without mechanical ventilation on day 14
Measure: Patients alive and without mechanical ventilation on day 14 Time: 14 daysDescription: Percentage of patients alive and without mechanical ventilation on day 28
Measure: Patients alive and without mechanical ventilation on day 28 Time: 28 daysDescription: Percentage of patients alive and without vasopressors on day 28
Measure: Patients alive and without vasopressors on day 28 Time: 28 daysDescription: Number of days without vasopressors for 28 days
Measure: Days without vasopressors for 28 days Time: 28 daysDescription: Percentage of patients cured at 15 days
Measure: Patients cured at 15 days Time: 15 daysDescription: Percentage of patients with each adverse event
Measure: Incidence of Treatment-Emergent Adverse Events Time: 1 yearAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports